Share Name Share Symbol Market Type Share ISIN Share Description
Netscientific LSE:NSCI London Ordinary Share GB00B9F4MT28 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.50p +4.76% 11.00p 10.00p 12.00p 13.00p 10.00p 12.00p 272,514 14:00:58
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.4 -9.6 -13.6 - 8.64

NetScientific PLC Glycotest Receives First $3m Tranche from Fosun

14/02/2019 12:07pm

UK Regulatory (RNS & others)

Netscientific (LSE:NSCI)
Historical Stock Chart

2 Months : From Jan 2019 to Mar 2019

Click Here for more Netscientific Charts.


RNS Number : 0477Q

NetScientific PLC

14 February 2019

NetScientific plc

("NetScientific" or the "Company" or the "Group")

Glycotest Inc. Receives $3 Million Initial Tranche from $10 Million Series A Financing

London, UK - February 14, 2019 - Further to its earlier related announcement on 22 October 2018, NetScientific plc ("NetScientific", AIM: NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company Glycotest Inc. has received the initial $3m tranche of the $10m Series A financing round with Shanghai Fosun Pharmaceutical Co., Ltd. ("Fosun Pharma"), a leading healthcare group based in China.

This initial tranche will primarily serve to drive Glycotest's proprietary HCC Panel towards commercialisation in the US and to transfer the technology to Fosun Pharma, who will commercialise it in China.

Funding of the remaining $7m is due on completion of certain milestones.

Commenting on the news, NetScientific's Chief Executive Officer and Chairman of Glycotest Inc., Francois R. Martelet said: "The receipt of the first tranche of financing will kickstart Glycotest's commercialisation activities and moves them closer to becoming the first company to commercialise an assay for the early detection and surveillance of early-stage liver cancer, where there is a huge unmet need. We are proud that Glycotest's ongoing efforts are materialising into tangible results and look forward to the progress to come."

The full text of the announcement from Glycotest Inc. can be found below.

# # #

For more information, please contact:

  NetScientific                                   Tel: +44 (0)20 3514 1800 
   François R. Martelet, 
   M.D., CEO 
   Ian Postlethwaite, CFO 
  Consilium Strategic Communications 
   Mary-Jane Elliott / Chris Welsh                Tel: +44 (0)20 3709 5700 
   / Laura Thornton             
  WHIreland (NOMAD and Broker)                    Tel: +44 (0)20 7220 1666 
   Chris Fielding / Jessica Cave 
   / Chris Viggor 

Glycotest, Inc. Receives $3 Million First Tranche of $10 Million Series A Financing

New York, NY-February 14, 2019. Glycotest, Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis, announced today that the Company has received the first $3 million tranche of the $10 million Series A funding round from Shanghai Fosun Pharmaceutical Co., Ltd. ("Fosun Pharma").

The focus of this strategic investment is the advancement of the HCC Panel toward commercial launch in the United States, transfer of the HCC Panel technology to Fosun Pharma's diagnostic subsidiary for commercialization in China, and further development of pipeline tests for liver fibrosis and cholangiocarcinoma, the second most prevalent form of liver cancer. Under the terms of the agreement, Fosun Pharma receives a 40% equity stake in Glycotest and an exclusive license to manufacture and sell the Glycotest HCC Panel blood test in China in return for a royalty on sales to Glycotest. Funding of the remaining $7 million is due on completion of certain milestones.

Glycotest's HCC Panel is a unique algorithm-driven biomarker panel that takes advantage of the Company's patented fucosylated biomarker technology and is intended for surveillance of patients known to be at risk for hepatocellular carcinoma (HCC). HCC is the predominant form of primary liver cancer and fastest growing cause of cancer death in the United States with an estimated three million or more at-risk patients in the US who are eligible for HCC surveillance testing. Currently, many patients with HCC are not identified until they have later stage disease and are no longer eligible for curative therapy because tests available now are ineffective for identifying patients with curable early-stage HCC. Three clinical studies involving over 480 patients have shown the HCC Panel to be able to identify patients with curable early-stage HCC more effectively than AFP, the currently dominant blood test for HCC.

CEO Lawrence Cohen said, "Now that Glycotest has received the first tranche of our $10 million Series A funding round we can begin the important work of making the HCC Panel available to physicians and patients in the US and China who need an effective test for detecting curable early-stage liver cancer."

About Glycotest, Inc.

Glycotest is a private liver disease diagnostics company commercializing novel clinical laboratory testing services for patients with serious liver disease. Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry. The Company's pipeline includes tests for liver cancers as well as liver fibrosis-cirrhosis. Glycotest's mission is to reduce mortality and increase survival for the growing populations at risk due to serious underlying liver disease, including both viral hepatitis and non-viral forms of hepatitis such as NASH. Glycotest was founded in 2012 on proprietary technology that originated at the Philadelphia area institutions Baruch S. Blumberg Institute and Drexel University College of Medicine. Learn more at www.Glycotest

About Fosun Pharma

Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a leading healthcare group in the PRC. Adhering to the mission of improving human health, Fosun Pharma's business covers all key sectors of healthcare industry chain, including pharmaceutical manufacturing and R&D, healthcare services, medical devices and medical diagnosis, as well as pharmaceutical distribution and retail. Fosun Pharma always regards innovation as the driving force for its business growth. The company continuously optimized its pharmaceutical R&D system that integrates biosimilars and innovative drugs and has established international R&D teams in China, the United States, India, etc., forming a globally interactive R&D system. Fosun Pharma maintains a national recognized enterprise technology center and establishes innovative chemical drugs platform, biologics platform, high-value generic drugs platform and cell-therapy platform. At present, Fosun Pharma maintains the leading position with its core products in various therapeutic areas, including oncology, cardiovascular system, central nervous system, blood system, metabolism and alimentary system and anti-infection. All products occupy the leading position in each market segment.

About NetScientific

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

February 14, 2019 07:07 ET (12:07 GMT)

1 Year Netscientific Chart

1 Year Netscientific Chart

1 Month Netscientific Chart

1 Month Netscientific Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190320 15:05:21